PLGA-Based Nano-Adjuvant Enhances Mucosal and Systemic Immunity in Chicks

Study Background and Research Question

H9N2 avian influenza virus (AIV) remains a persistent threat to poultry health, primarily due to its ability to infect hosts via respiratory and digestive tracts and establish secondary colonization in the intestinal epithelium. Standard vaccination strategies—such as inactivated and live attenuated vaccines—are effective at inducing humoral and cellular immunity but often fail to generate robust mucosal immunity, leaving a critical gap in protection (paper). Since mucosal IgA responses are essential for blocking initial infection and reducing viral shedding, the development of novel adjuvants capable of inducing both systemic and mucosal immunity is a priority in avian immunology.

Key Innovation from the Reference Study

The major innovation in this work is the creation of a multi-component nanoadjuvant, PEI-LSP-RA-PLGA, constructed using poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating Lagenaria siceraria polysaccharide (LSP) and retinoic acid (RA), and surface-modified with polyethylenimine (PEI). This system leverages the controlled-release and biocompatibility of PLGA, the immunoactive properties of LSP and RA, and the enhanced cellular uptake afforded by PEI, to create a vaccine adjuvant capable of:

• Prolonged antigen release over 21 days
• Targeted delivery to the intestinal tract
• Simultaneous stimulation of systemic (IgG) and mucosal (IgA) immunity
• Activation of key chemokine pathways (CCR9/CCR6 via CCL20/CCL25) and mucosal immune signaling (Toll-like and NOD-like receptor pathways)

This approach addresses long-standing challenges in poultry vaccine development by enhancing both the magnitude and localization of the immune response (paper).

Methods and Experimental Design Insights

The research team utilized a double-layer (W1/O/W2) nanoparticle fabrication method to co-encapsulate both hydrophilic (LSP) and hydrophobic (RA) agents within PLGA nanoparticles. The resulting PEI-LSP-RA-PLGA nanoadjuvant exhibited a mean size of 200 nm and a moderately positive zeta potential (13 mV), which together promote efficient cellular uptake and mucosal tissue penetration. The nanoparticles were mixed with inactivated H9N2 antigen and injected into chicks. The experimental design included:

• Characterization of nanoparticle size, charge, and stability
• Assessment of antigen release kinetics in vitro and in vivo
• Measurement of serum IgG and intestinal IgA by ELISA post-vaccination
• Cytokine profiling and evaluation of immune organ development
• Histological analysis of intestinal morphology
• In vivo fluorescent imaging to track nanoparticle distribution and antigen retention
• Gene expression and pathway analysis to elucidate mechanisms of mucosal targeting

These methods were chosen to comprehensively evaluate both the immunogenicity and tissue-targeting performance of the nanoadjuvant system (paper).

Core Findings and Why They Matter

The PEI-LSP-RA-PLGA nanoadjuvant produced several notable outcomes:

• Sustained Antigen Release: The nanoadjuvant maintained antigen presence at the injection site for up to 21 days, supporting prolonged immune stimulation (paper).
• Enhanced Systemic and Mucosal Immunity: Vaccinated chicks exhibited a 132.83% increase in serum IgG and a 115.12% increase in intestinal IgA, compared to conventional adjuvant controls (paper).
• Improved Immune Organ and Intestinal Structure: The adjuvant promoted immune organ development, increased the number of IgA+ cells in intestinal tissue, and improved small intestine morphology, suggesting better mucosal barrier function.
• Mechanistic Insights: Gene expression analysis revealed that the nanoadjuvant’s targeting of the intestine was mediated by activation of CCR9/CCR6 signaling in response to CCL20 and CCL25, as well as triggering key innate immune pathways (Toll-like and NOD-like receptor signaling).

These results indicate that the PEI-LSP-RA-PLGA nanoadjuvant can elicit a broader, more durable immune response, which is particularly valuable for controlling enteric pathogens like H9N2 (paper).

Comparison with Existing Internal Articles

Several recent overviews on the use of advanced hydrophilic fluorescent dyes, such as Sulfo-Cy5 carboxylic acid, underscore the importance of sensitive and reliable immunofluorescence detection in both neuroscience and immunology research (internal_article1, internal_article2). In the context of the PLGA-based nanoadjuvant study, in vivo imaging and cell tracking were essential for demonstrating the sustained release and tissue targeting properties of the nanoparticles. Internal literature has highlighted the role of sulfonated hydrophilic dyes like Sulfo-Cy5 in minimizing fluorescence quenching and improving the accuracy of such imaging, a feature critical for validating mechanistic insights into mucosal targeting (internal_article4). Moreover, these reviews note the workflow advantages of using highly water-soluble dyes for protein and peptide labeling, which is directly relevant to the antibody detection and cellular assays employed in this nanoadjuvant research (internal_article5).

Protocol Parameters

• fluorescent imaging of nanoparticles | excitation max 646 nm, emission max 662 nm | in vivo intestinal tracking | matches dye properties for tracking antigen/nanoparticle distribution | product_spec
• nanoparticle size | 200 nm | optimal for mucosal tissue penetration and uptake by immune cells | balances stability and tissue targeting | paper
• antigen release duration | 21 days | enables prolonged immune stimulation | supports single-dose efficacy | paper
• IgA/IgG response evaluation | ELISA, fold-increase vs control | immunogenicity assessment | quantifies adjuvant efficacy | paper
• protein and peptide labeling for antibody detection | use of hydrophilic fluorescent dye (e.g., Sulfo-Cy5) | boosts signal/noise for immunological assays | reduces fluorescence quenching and increases reproducibility | workflow_recommendation

Limitations and Transferability

While the PEI-LSP-RA-PLGA nanoadjuvant shows substantial promise, several limitations merit consideration:

• The current study is limited to a chick model, and immune system responses may differ in other avian species or mammals (paper).
• Long-term safety and scalability of this nanoadjuvant require further validation before field deployment.
• The complexity of nanoparticle fabrication may affect reproducibility and cost in larger-scale vaccine production.

Transferability to other mucosal vaccine applications is theoretically promising, but further studies are needed to confirm efficacy in other pathogens and hosts (paper).

Why this cross-domain matters, maturity, and limitations

The cross-domain application of hydrophilic fluorescent dyes, such as Sulfo-Cy5 carboxylic acid, in immunology and neuroscience enables improved visualization of nanoparticle biodistribution and immune cell tracking. This methodological bridge enhances the reliability of mechanistic studies in both fields, as high-sensitivity fluorescent labeling is essential for verifying mucosal targeting and antigen fate. However, the translation of these imaging approaches from basic to applied vaccine development is still maturing, with further standardization needed for regulatory acceptance (internal_article2).

Outlook

The PEI-LSP-RA-PLGA platform demonstrates a rationally engineered approach for overcoming the limitations of traditional adjuvants, offering sustained antigen delivery and robust mucosal immune induction. If further validated, this strategy could help close critical gaps in the prevention of enteric and respiratory pathogens in poultry and potentially in other species. The integration of advanced imaging tools, as highlighted in internal reviews, will continue to play a pivotal role in refining nanovaccine designs and confirming mechanistic hypotheses (paper; internal_article1).

Research Support Resources

For researchers aiming to replicate or extend fluorescence-based tracking of nanovaccine performance, Sulfo-Cy5 carboxylic acid (SKU A8137) from APExBIO provides a robust, water-soluble fluorescent dye for protein and peptide labeling. Its minimized fluorescence quenching and high quantum yield are advantageous for sensitive in vivo or ex vivo imaging required in mucosal immunity and nanoparticle biodistribution studies (workflow_recommendation).